Compare Regeneron Pharmaceuticals Inc (REGN) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.99. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Consumer Discretionary Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| REGN | XLY | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | — |
52-Week High | $812.27 | $124.52 |
52-Week Low | $545.46 | $105.64 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
XLY trades at $114.61, down 0.72% on the day, with technical indicators showing a bearish trend as the price approaches key support levels. The ETF faces headwinds from consumer sentiment concerns but maintains 100% analyst buy ratings. Recent news highlights XLY's strong track record in consumer discretionary exposure despite inflationary pressures affecting the sector.
The outlook remains cautiously optimistic with analyst support, though technical weakness and consumer spending risks require monitoring. Investment opportunity lies in potential sector recovery, while risks include persistent inflation and declining consumer confidence affecting discretionary spending patterns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
